Investor Presentaiton
Demographics and Baseline Characteristics
Daiichi-Sankyo
Dato-DXd
Docetaxel
Characteristic
Dato-DXd
N=299
Docetaxel
N=305
Characteristic
N=299
N=305
Age, median (range), years
63 (26-84)
64 (24-88)
Current or former smoker, n (%)
238 (80)
251 (82)
Present
50 (17)
51 (17)
Male, n (%)
183 (61)
210 (69)
Actionable genomic
alterations, n (%)
EGFR mutation
39 (13)
45 (15)
Asian
119 (40)
120 (39)
White
123 (41)
126 (41)
Brain metastasis at baseline, n (%) b
50 (17)
47 (15)
Race, n (%)
1
167 (56)
174 (57)
Black or African American
6 (2)
4 (1)
Prior lines of therapy,
Othera
51 (17)
55 (18)
2
108 (36)
102 (33)
n (%)
≥3
22 (7)
28 (9)
0
89 (30)
94 (31)
ECOG PS, n (%)
1
210 (70)
211 (69)
Platinum containing
297 (99)
305 (100)
Non-squamous
234 (78)
234 (77)
Previous systemic
therapy, n (%)
Histology, n (%)
Squamous
65 (22)
71 (23)
Anti-PD-(L)1
Targeted
263 (88)
268 (88)
46 (15)
50 (16)
ECOG PS, Eastern Cooperative Oncology Group performance status; PD-(L)1, programmed cell death 1 (ligand 1).
*Race data missing for 8 patients in each arm. "Patients who are no longer symptomatic and who require no treatment with corticosteroids and anticonvulsants and have recovered from acute toxic effects of radiation are eligible.
In the Dato-DXd arm, 2 patients did not receive prior treatment with a platinum-containing therapy and 1 patient with actionable genomic alterations did not receive previous targeted therapy, deviating from the protocol.
Data cutoff 29 March 2023.
7View entire presentation